Research relating to BIOQUELL

Summary: 53% reduction in the rate of C.diff associated disease when comparing the period when BIOQUELL was used with pre-intervention period when epidemic strain was present.
Boyce et al, Infect Cont Hosp Epidemiol 2008; 29:723-729.

Summary: 77% reduction in the risk of VRE acquisition where patient admitted to a bioquelled (rather than cleaned) room.
Passaretti. ICAAC Conference, DC, US.2008.

Summary: Annual cost-benefit of >300% associated with reduction in C.diff acquisition during BIOQUELL deployment.
Cooper and O’leary. Infection Prevention Society (IPS) Conference, Harrogate, UK.2009.

Summary: Use of BIOQUELL operationally feasible, even in times of high census.
Otter et al, Infect Control Hosp Epidemiol 2009; 30:574-577.

Summary: Serratia outbreak in a neonatal intensive care unit.
Bates and Pearse, J Hosp Infect 2005; 61:364-366

Summary: Successful eradication of persistent environmental of persistent environmental MRSA.
Jeanes et al. J Hosp infect 2005;61: 85-86

Summary: Control of an MRSA outbreak using BIOQUELL.
Dryden et al ICAAC Conference, Chicago, US 2007

Summary: Nosocomial pathogens survive for extended periods on surfaces and are inactivated by BIOQUELL’s technology.
Otter and French. J. Clin. Microbiol. 2009; 47:205-207

Summary: Efficacy of BIOQUELL over Mycobacterium Tuberculosis.
Hall et al. J. Clin. Microbiol. 2007: 45;810-815